Department of Medicine, University of British Columbia, Vancouver, Canada.
Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada.
BMC Pulm Med. 2023 Mar 13;23(1):84. doi: 10.1186/s12890-023-02376-w.
The pathophysiology, evolution, and associated outcomes of post-COVID dyspnea remain unknown. The aim of this study was to determine the prevalence, severity, and predictors of dyspnea 12 months following hospitalization for COVID-19, and to describe the respiratory, cardiac, and patient-reported outcomes in patients with post-COVID dyspnea.
We enrolled a prospective cohort of all adult patients admitted to 2 academic hospitals in Vancouver, Canada with PCR-confirmed SARS-CoV-2 during the first wave of COVID between March and June 2020. Dyspnea was measured 3, 6, and 12 months after initial symptom onset using the University of California San Diego Shortness of Breath Questionnaire.
A total of 76 patients were included. Clinically meaningful dyspnea (baseline score > 10 points) was present in 49% of patients at 3 months and 46% at 12 months following COVID-19. Between 3 and 12 months post-COVID-19, 24% patients had a clinically meaningful worsening in their dyspnea, 49% had no meaningful change, and 28% had a clinically meaningful improvement in their dyspnea. There was worse sleep, mood, quality of life, and frailty in patients with clinically meaningful dyspnea at 12 months post-COVID infection compared to patients without dyspnea. There was no difference in PFT findings, troponin, or BNP comparing patients with and without clinically meaningful dyspnea at 12 months. Severity of dyspnea and depressive symptoms at 3 months predicted severity of dyspnea at 12 months.
Post-COVID dyspnea is common, persistent, and negatively impacts quality of life. Mood abnormalities may play a causative role in post-COVID dyspnea in addition to potential cardiorespiratory abnormalities. Dyspnea and depression at initial follow-up predict longer-term post-COVID dyspnea, emphasizing that standardized dyspnea and mood assessment following COVID-19 may identify patients at high risk of post-COVID dyspnea and facilitating early and effective management.
新冠病毒感染后呼吸困难的病理生理学、演变和相关结局尚不清楚。本研究旨在确定 COVID-19 住院后 12 个月呼吸困难的患病率、严重程度和预测因素,并描述患有新冠后呼吸困难患者的呼吸、心脏和患者报告结局。
我们纳入了 2020 年 3 月至 6 月加拿大温哥华 2 所学术医院因 PCR 确认的 SARS-CoV-2 住院的所有成年患者的前瞻性队列。使用加利福尼亚大学圣地亚哥短气问卷在初始症状出现后 3、6 和 12 个月测量呼吸困难。
共纳入 76 例患者。在 COVID-19 后 3 个月和 12 个月时,49%的患者存在有临床意义的呼吸困难(基线评分>10 分),46%的患者存在有临床意义的呼吸困难。在 COVID-19 后 3 至 12 个月期间,24%的患者呼吸困难有临床意义的恶化,49%的患者无明显变化,28%的患者呼吸困难有临床意义的改善。与无呼吸困难的患者相比,新冠感染后 12 个月有临床意义的呼吸困难的患者睡眠、情绪、生活质量和虚弱程度更差。在 COVID-19 后 12 个月,与无临床意义的呼吸困难患者相比,呼吸困难患者的 PFT 发现、肌钙蛋白或 BNP 没有差异。3 个月时呼吸困难严重程度和抑郁症状预测 12 个月时呼吸困难严重程度。
新冠后呼吸困难很常见,且持续存在,对生活质量有负面影响。除了潜在的心肺异常外,情绪异常可能在新冠后呼吸困难中起因果作用。初始随访时的呼吸困难和抑郁症状预测长期新冠后呼吸困难,这强调了 COVID-19 后标准化呼吸困难和情绪评估可能识别出有新冠后呼吸困难高风险的患者,并促进早期和有效的管理。